Preparation of breviscapine nanosuspension and its pharmacokinetic behavior in rats

Chinese Journal of Natural Medicines

Volumn 5, Issue 1, 2007, Pages 50-55

  She, Zou Yan ^a   Ke, Xue ^a   Ping, Qi Neng ^a   Xu, Bo Hui ^a   Chen, Li Li ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Breviscapine; Dissolution; Emulsification diffusion; Nanosuspension; Pharmacokinetics; Solubility

Indexed keywords

BREVISCAPINE; NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG TRANSPORT; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE TRANSIT TIME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAFILTRATION; ZETA POTENTIAL;

EID: 33846998611     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rational for development and what we can expect for the future[J]. Adv Drug Deliver Rev,2001, 47(1): 3-19.
2. Bohm BH, Muller RH. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs[J]. Pharm Sci Technol Today, 1999, 2(8):336-339.
3. Trotta M, Gallarate M, Pattarino F, et al. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions[J]. J Controlled Release, 2001, 76(1-2):119-128.
4. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs[J]. Int J Pharm, 1995, 125(1):91-97.
5. Cui JM, Wu S. The advance on the research of breviscapine[J]. Nat Prod Res Dew, 2003,15(3): 255-258.
6. Ge QH, Zhou Z, Zhi XJ, et al. Pharmacokinetics and absolute bioavailability of breviscapine in beagle dog[J]. Chin J Pharm, 2003,34(12):618-620.
7. Wehrle P, Magenheim B, Benita S. The influence of process parameters on the PLA nanoparticle size distribution evaluated by means of factorial design[J]. J Pharm Biopharm, 1995,41(1):19-26.
8. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs[J]. Int J Pharm, 2004,284 (1-2): 109-122.
9. Zhang YM. Bioavailability of isoflavone in soybeans[J]. Foreign Med Sci, 2001,28(2): 105.
10. Wang QW, Mei QB, Zhou SY, et al. Study on the bioavailability of genistein capsule in SD rats[J]. Pharm J Chin PLA, 2003,19(3): 189-191.
11. Sfakianos J, Coward L, Kirk M, et al. Intestinal uptake and biliary excretion of the isoflavone genistein in rats[J]. J Nutr, 1997, 127 (7): 1260-1268.
12. Mo Y, Zhang JS. The development of colon-targeted drug delivery system[J]. Chin J New Drugs, 1999,8 (6): 368.
13. Day AJ, Gee JM, DuPont MS, et al. Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter[J]. Biochem Pharmacol, 2003,65(7): 1199-1206.
14. Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications [J]. Int J Pharm, 2001, 214(1-2): 83-85.
15. Zhang HY, Ping QN, Guo JX, et al. Parmacokinetics of breviscapine and its β-cyclodextrin complextrin complex in rats[J]. Acta Pharm Sin, 2005, 40(6): 563-567.
16. Chen XJ, Wang GJ. The role of transporters in the drug absorption, distribution and elimination and its significance in the new drug development[J]. J China Pharm Univ, 2003,34(6): 483-486.
17. Evers R, Zaman GJ, van Deemter L, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells[J]. J Clin Invest, 1996, 97 (5): 1211-1218.